Friday, 18 September 2020

Beijing Drug Admin, Zimmer sign musculoskeletal MoU

16 November 2012 | News | By BioSpectrum Bureau

Beijing Drug Admin, Zimmer sign musculoskeletal MoU

Zimmer and Beijing Drug Administration (BJDA) sign MoU to jointly deliver musculoskeletal health training

Zimmer and Beijing Drug Administration (BJDA) sign MoU to jointly deliver musculoskeletal health training

Singapore: Zimmer Holdings, a global leader in musculoskeletal health, has signed a memorandum of understanding (MoU), with the Beijing Drug Administration (BJDA) to jointly hold training sessions at Montagne, Zimmer's wholly-owned Chinese subsidiary.

The trainings will be dedicated to the mutual sharing of knowledge and expertise in R&D, quality and regulation related to musculoskeletal health. The partnership aims to allow BJDA to gain industry knowledge and to understand Zimmer and its products through dialogues and trainings undertaken by its State Inspectors.

The goal of the agreement also includes strengthening production and inspection expertise at Chinese medical device companies to ensure the delivery of safe and quality orthopaedic medical devices.

Ms Lu Aili, deputy director general, Beijing Drug Administration, said that, "The trainings provide a platform by which both sides will be able to gain from each other's strengths related to medical devices, especially in the area of orthopaedic reconstructive. Overall, BJDA is committed to working with all our partners and industry stakeholders to achieve the goals set forth in the 12th five-year-plan of upgrading the healthcare industry and ensuring citizens' health and quality of life."

According to recently released statistics by the China National Committee on Aging, the number of Chinese senior citizens is expected to increase from the current 185 million to 487 million, or 35 percent of the population, by 2053. This joint effort by Zimmer and the BJDA to hold training sessions lays the groundwork for additional opportunities to share knowledge in the near future.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls